North Shore InnoVentures Receives $1.65 Million from the Massachusetts Life Sciences Center Award is part of $5 million grant to Colleges and Incubators to fund Lab/Facility and Equipment Upgrades in North Shore regionRead more
North Shore InnoVentures Receives $1.65 Million from the Massachusetts Life Sciences Center Award is part of $5 million grant to Colleges and Incubators to fund Lab/Facility and Equipment Upgrades in North Shore regionRead more
Dr. Richard Wylie, President of Endicott College, Joins North Shore InnoVentures’ Board of DirectorsRead more
Beverly, MA- November 12, 2014- Navolta was issued patent 8875981, “System and method for a microreactor”Read more
Five Startup Entrepreneurs of North Shore InnoVentures Technology Incubator Have Been Past WinnersRead more
MCC Global Laboratories, Inc. Moves from France to MassachusettsRead more
A Milestone Achieved: Over $100 Million in Grants and Equity Raised Since 2009Read more
State energy officials announced today that awards totaling $530,000 will be given to four Massachusetts small business cleantech incubators. North Shore InnoVentures will receive $165,000 over a three-year period. Other awardees include Chesnut Innovation Center (Amesbury), Greentown Labs (Somerville), and TechSandBox (Hopkinton).Read more
NSIV is featured in a special section in the 2015-2016 edition of The Index of the Massachusetts Innovation Economy, published annually by the Massachusetts Technology Collaborative’s Innovation Institute. The special analysis, “Collaborative Workspaces in the Commonwealth,” takes a look at the different types of spaces, how many of each, the services offered and shows someRead more
North Shore InnoVentures Incubator Receives Nonprofit Excellence Award from Essex County Community Foundation Recent awards demonstrate NSIV’s economic value to the North Shore technology communityRead more
NSIV member, Cellanyx Diagnostics, was awarded the best prostate cancer biomarker poster presentation at the recent 2016 American Urological Association annual meeting. “Cellanyx is currently developing phenotypic tests to address an important unmet clinical need in prostate cancer risk stratification by providing quantitative assessment of tumor aggressiveness and metastatic potential that complements the standard-of-care GleasonRead more
Interested in incubating your company with InnoVenture Labs? Submit your application today!